Loading...
•
Dec 31, 2021
Vanda Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
Vanda Pharmaceuticals reported a 1% increase in total net product sales from HETLIOZ® and Fanapt®, reaching $68.0 million in Q4 2021, and a net income of $7.1 million compared to $8.2 million in Q4 2020.
Total net product sales from HETLIOZ® and Fanapt® were $68.0 million, a 1% increase compared to the fourth quarter of 2020.
HETLIOZ® net product sales were $44.1 million compared to $44.2 million in the fourth quarter of 2020.
Fanapt® net product sales were $24.0 million, a 2% increase compared to the fourth quarter of 2020.
Net income was $7.1 million compared to $8.2 million in the fourth quarter of 2020.
Revenue by Segment
Forward Guidance
Vanda expects full year 2022 total revenues to be between $240 million and $280 million, HETLIOZ® net product sales between $150 million and $180 million, Fanapt® net product sales between $90 million and $100 million, and year-end 2022 Cash to be greater than $440 million.
Positive Outlook
- Full year 2022 total revenues expected to be between $240 million and $280 million
- HETLIOZ® net product sales expected to be between $150 million and $180 million
- Fanapt® net product sales expected to be between $90 million and $100 million
- Year-end 2022 Cash expected to be greater than $440 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...